Empagliflozin-pretreated mesenchymal stem cell-derived small extracellular vesicles
1 paper4 findings
- 1 lab in 1 country
- Funders: China Postdoctoral Science Foundation and 5 more
- Animals1
Outcomes
4Angiogenesis
upin rats1
1 study
Angiogenesis
upin rats1
Empagliflozin-pretreated mesenchymal stem cell-derived small extracellular vesicles activate angiogenesis in rats.
“In the SD rat model of MI, EMPA-sEV inhibited myocardial apoptosis and promoted angiogenesis in the infarct marginal areas compared with the MSC-sEV.”
Animalsin the SD rat model of MIheart
Oxidative medicine and cellular longevityFeb 18, 2023
Apoptosis
downin rats1
1 study
Apoptosis
downin rats1
Empagliflozin-pretreated mesenchymal stem cell-derived small extracellular vesicles inhibit apoptosis in rats.
“In the SD rat model of MI, EMPA-sEV inhibited myocardial apoptosis and promoted angiogenesis in the infarct marginal areas compared with the MSC-sEV.”
Animalsin the SD rat model of MIheart
Oxidative medicine and cellular longevityFeb 18, 2023
Cardiac function
upin rats1
1 study
Cardiac function
upin rats1
Empagliflozin-pretreated mesenchymal stem cell-derived small extracellular vesicles improve cardiac function in rats.
“Meanwhile, EMPA-sEV reduced infarct size and improved cardiac function.”
Animalsafter myocardial infarctionheart
Oxidative medicine and cellular longevityFeb 18, 2023
Infarct size
downin rats1
1 study
Infarct size
downin rats1
Empagliflozin-pretreated mesenchymal stem cell-derived small extracellular vesicles decrease infarct size in rats.
“Meanwhile, EMPA-sEV reduced infarct size and improved cardiac function.”
Animalsafter myocardial infarctionheart
Oxidative medicine and cellular longevityFeb 18, 2023